Emergent BioSolutions Acquires Trubion Pharmaceuticals for $96,800,000

  • Feed Type
  • Date
  • Company Name
    Trubion Pharmaceuticals
  • Mailing Address
    2401 4th Ave Seattle, WA 98121
  • Company Description
    Trubion Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to treat inflammatory disease and cancer.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Under the terms of the agreement each share of Trubion Pharmaceuticals common stock will be converted into the right to receive an up-front payment of $1.365 per share in cash and 0.1641 shares of Emergent BioSolutions’ common stock. The up-front payment represents a value of $4.55 per share, or approximately $96.8 million.

Trending on Xconomy